$214 Million is the total value of VHCP Management III, LLC's 17 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 6.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MIST | New | Milestone Pharmaceuticals Inc | $56,106,000 | – | 2,066,529 | +100.0% | 26.20% | – |
| AXSM | Buy | Axsome Therapeutics Inc | $41,492,000 | +173.0% | 1,611,329 | +50.9% | 19.37% | +118.6% |
| RARX | Buy | Ra Pharmaceuticals | $20,157,000 | +51.3% | 670,350 | +12.7% | 9.41% | +21.2% |
| KALV | Sell | Kalvista Pharmaceuticals | $14,129,000 | -49.1% | 637,884 | -34.3% | 6.60% | -59.3% |
| OBSV | Obseva SA | $13,117,000 | -11.6% | 1,159,789 | 0.0% | 6.12% | -29.2% | |
| PTGX | Buy | Protagonist Therapeutics Inc | $12,986,000 | +27.7% | 1,072,348 | +32.5% | 6.06% | +2.2% |
| LJPC | Buy | La Jolla Pharmaceuticals | $11,580,000 | +79.5% | 1,251,898 | +24.7% | 5.41% | +43.7% |
| TCDA | Sell | Tricida Inc | $11,433,000 | -54.5% | 289,746 | -55.5% | 5.34% | -63.6% |
| BCRX | Sell | BioCryst Pharmaceuticals Inc | $10,264,000 | -58.8% | 2,708,207 | -11.5% | 4.79% | -67.0% |
| ORTX | Sell | Orchard RX Ltd | $9,461,000 | -34.8% | 676,252 | -16.6% | 4.42% | -47.7% |
| MRNS | Marinus Pharmaceuticals Inc | $5,225,000 | -0.7% | 1,258,964 | 0.0% | 2.44% | -20.4% | |
| KNSA | Sell | Kiniksa Pharmaceuticals Ltd | $4,229,000 | -28.6% | 312,320 | -4.7% | 1.98% | -42.8% |
| BLPH | Bellerophon Therapeutics | $1,450,000 | -8.1% | 2,417,227 | 0.0% | 0.68% | -26.4% | |
| KDMN | Sell | Kadmon Holdings Inc. | $870,000 | -76.3% | 422,141 | -69.6% | 0.41% | -81.0% |
| CNST | Constellation Pharmaceuticals | $819,000 | -9.3% | 66,667 | 0.0% | 0.38% | -27.4% | |
| GEMP | Sell | Gemphire Therapeutics | $646,000 | -35.4% | 798,066 | -8.2% | 0.30% | -48.2% |
| PTI | Sell | Proteostasis Therapeutics Inc | $216,000 | -76.3% | 221,267 | -69.4% | 0.10% | -81.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
| Obseva SA | 6 | Q4 2019 | 15.8% |
| Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
| Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
| Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
| BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
| Tricida Inc | 5 | Q3 2019 | 15.0% |
| Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
| Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
| Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-22 |
| 4 | 2024-02-08 |
| 4 | 2024-02-01 |
| 4 | 2024-01-29 |
| 4 | 2024-01-24 |
| 4 | 2024-01-19 |
| 4 | 2024-01-16 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.